Quality of Life in Hidradenitis Suppurativa: An Update

Pavel V. Chernyshov, Andrew Y. Finlay, Lucia Tomas-Aragones, Francoise Poot, Francesca Sampogna, Servando E. Marron, Sergey V. Zemskov, Damiano Abeni, Thrasyvoulos Tzellos, Jacek C. Szepietowski and Christos C. Zouboulis
Additional contact information
Pavel V. Chernyshov: Department of Dermatology and Venereology, Bogomolets National Medical University, 01601 Kiev, Ukraine
Andrew Y. Finlay: Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK
Lucia Tomas-Aragones: Department of Psychology, University of Zaragoza, 50009 Zaragoza, Spain
Francoise Poot: Department of Dermatology, University Hospital Erasme, 1070 Brussels, Belgium
Francesca Sampogna: Clinical Epidemiology Unit, IDI-IRCCS, 00167 Rome, Italy
Servando E. Marron: Aragon Psychodermatology Research Group (GAI + PD), Department of Dermatology, University Hospital Miguel Servet, 50009 Zaragoza, Spain
Sergey V. Zemskov: Department of General Surgery, Bogomolets National Medical University, 01601 Kiev, Ukraine
Damiano Abeni: Clinical Epidemiology Unit, IDI-IRCCS, 00167 Rome, Italy
Thrasyvoulos Tzellos: Department of Dermatology, NLSH University Hospital, 8092 Bodø, Norway
Jacek C. Szepietowski: European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany
Christos C. Zouboulis: European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany

IJERPH, 2021, vol. 18, issue 11, 1-14

Abstract: Knowledge on hidradenitis suppurativa/acne inversa (HS) is rapidly increasing. HS has a profound impact on patients and their family life. Several factors, such as comorbidities, unemployment and HS severity, make this impact even more severe. The most widely used instrument to measure this impact is the dermatology-specific DLQI. We also identified six HS-specific health-related quality of life (HRQoL) instruments. Of them, HIDRAdisk, HSIA, HiSQOL and HSQoL-24 are better validated but there is still lack of experience of its use. Several treatment methods showed positive effect on patients’ HRQoL. Surgery remains a method with a substantial positive effect on HRQoL. Several studies confirming a positive effect of adalimumab on the HRQoL of patients with HS were published during the last three years. Data on the influence of several other biologics on HRQoL of HS patients are controversial or based on studies with a small number of patients.

Keywords: hidradenitis suppurativa; quality of life; impact; treatment; biologics; surgery (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/11/6131/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/11/6131/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:11:p:6131-:d:569895

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().